Company Overview and News

 
Pantoro Ltd increases ownership to 100% at producing high grade gold mine

2016-07-15 proactiveinvestors.com.au
Pantoro Ltd (ASX:PNR) has increased its ownership to 100% by acquiring the remaining 20% of the Halls Creek Project in Western Australia, which hosts the low cost, high grade Nicolsons Gold Mine. Recent drilling at Nicolsons discovered bonanza grade gold demonstrating that high grade mineralisation extends well beyond the current mine plan. Pantoro secured the remaining 20% of the project from Bulletin Resources Ltd (ASX:BNR) for 130 million Pantoro shares.

 
 
 
Appendix 3B

2016-05-06 asx.com.au

 
Pantoro Ltd moves to 100% ownership of Nicolsons producing gold mine

2016-05-02 proactiveinvestors.com.au
Pantoro Ltd (ASX:PNR), (formerly Pacific Niugini), is producing gold from the Nicolsons gold mine in Western Australia.

 
31 March 2016 Quarterly Reports

2016-04-29 asx.com.au

 
Blackham Resources Ltd swells Ore Reserves to 517,000 gold ounces

2016-04-19 proactiveinvestors.com.au
Blackham Resources Ltd (ASX:BLK) has defined a multi-million gold ounce resource base at the Matilda Gold Project in Western Australia.

 
Half Yearly Report and Accounts

2016-03-15 asx.com.au

 
 
Change in substantial holding

2016-03-01 asx.com.au

 
 
Change in substantial holding

2016-02-17 asx.com.au

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...